ABPAS	Alcian Blue periodic acid-Schiff
ACC	adenoid cystic carcinoma
AMACAR	alpha-methylacyl-CoA racemase
BC	breast cancer
BLIA	basal-like immune-activated
BLIS	basal-like immune-suppressed
CAP	cyclophosphamide + doxorubicin + cisplatin schedule
CEA	carcinoembryonic antigen
CK	cytokeratin
CR	complete response
CT	computed tomography
CTH	chemotherapy
DFS	disease-free survival
DXL	docetaxel
DXR	doxorubicin
EBUS	endobronchial ultrasound
ER	estrogen receptor
FAC	5-fluorouracil + doxorubicin + cyclophosphamide schedule
GATA-3	GATA binding protein 3
HE	hematoxylin and eosin
HER2	human epidermal growth factor receptor 2
LAR	luminal androgen receptor
MES	mesenchymal
mo	month
ND	not done
NVB	vinorelbine
OS	overall survival
PAX-8	paired-box gene 8
PD	progressive disease
PET-CT	positron emission tomography-computed tomography
PR	progesterone receptor
RTH	radiation therapy
SD	stable disease
SMA	smooth muscle actin
SLNB	sentinel node biopsy
TKI	tyrosine kinase inhibitor